Methoxy polyethylene glycol-epoetin beta

甲氧聚二醇重组人促红素

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMethoxy polyethylene glycol-epoetin beta
Drug Alias NameMethoxy polyethylene glycol-epoetin β甲氧基聚乙二醇重组人红细胞生成素Epoetin beta pegol (genetical recombination)MirceraR-1744 +[10] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemiaKidney Failure, ChronicRenal Insufficiency, Chronic +[4] 
Global Approved IndicationsAnemiaKidney Failure, Chronic
Approved Indications in ChinaAnemia
Original Approved Country/TerritoryEU
Original Approved Date2007/07/20
Country/TerritoryCzechiaBelgiumCanada +[52] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAlebund Pharmaceuticals (Hong Kong) LtdChugai Pharmaceutical Co LtdRoche Pharma (Schweiz) Ag +[6] 
Inactive CompaniesNational Cancer Institute
Active IndicationsAnemiaKidney Failure, ChronicRenal Insufficiency, Chronic
Inactive IndicationsLung Neoplasms

Other Information

ATC CodeB03XA03
Related LinksWikipediaDrugBank